Related by context. All words. (Click for frequent words.) 82 Ovarian PLCO Cancer 81 Prostate Lung Colorectal 81 Digital Mammographic Imaging 73 Screening Trial DMIST 70 DMIST 69 European Randomized Study 69 Ovarian Cancer Screening 69 PLCO 68 Stenting Trial CREST 68 Carotid Revascularization Endarterectomy vs. 68 Evaluation WISE 68 Cholesterol Levels SPARCL 67 Multi Ethnic Study 67 Trial NLST 67 Young Adults CARDIA 67 multicenter randomized clinical 66 Atherosclerosis MESA 66 Trial PCPT 66 CT Colonography Trial 66 Cervista HPV HR 66 Aggressive Reduction 66 number NCT# ClinicalTrials.gov 66 BRIM3 66 Intervention Trial GAIT 66 prospective multicentre 65 STRIDE PD 65 Prostate Cancer Prevention 65 CARDIA 65 Women Ischemia Syndrome 65 Group RTOG 65 BCIRG 65 Framingham Offspring 65 Gynecologic Oncology Group 65 prospective observational 65 Intervention Trial 65 ENESTnd 64 retrospective cohort study 64 multicenter phase 64 Multicenter AIDS 64 RECORD1 64 multicenter randomized controlled 64 Clinical Antipsychotic Trials 64 PRESEPT 64 ExTRACT TIMI 64 undergone radical prostatectomy 64 Dialysis Outcomes 64 ACRIN 64 longitudinal cohort study 64 ELCAP 64 LungAlert TM 64 CALGB 64 Health Initiative Observational 64 #rd Annual CTRC 64 Nymox NX 64 PERSEUS clinical program 64 Angiographic 64 Randomized Study 64 Phase IIIb study 64 ENDEAVOR IV 63 HCV SPRINT 63 Edge STudy 63 prospective observational cohort 63 NCI Cancer 63 HCV RESPOND 2 63 observational cohort study 63 NSABP B 63 Outpatient Setting 63 Multiethnic Study 63 REGARDS 63 substudy 63 Prospective Randomized 63 ONTARGET 63 Breast Specific Gamma 63 Gastric Cancer 63 Clinical Outcomes Utilizing Revascularization 63 Phase 1b clinical trials 63 Cancer Incidence Mortality 63 Clinical Outcome 63 CAMMS# 63 Automated Breast Ultrasound 63 Combination REOLYSIN R 63 SPIRIT FIRST 62 LUMINATE 62 Hormone Receptor Positive 62 Multicenter 62 AACR San Antonio 62 Pooled Analysis 62 endometriosis ovarian cysts 62 Accelerated Partial Breast Irradiation 62 evaluating tivozanib 62 Communities ARIC study 62 multicenter study 62 REVIVE Diabetes 62 Randomized Phase II 62 phase IIIb 62 randomized controlled clinical 62 adenoma recurrence 62 See CLINICAL PHARMACOLOGY 62 Oncotype DX TM 62 EURIDIS 62 miRview ™ mets 62 Metastatic Prostate Cancer 62 Coronary Artery Risk 62 CARDIA study 62 relapsed MM 62 BSGI MBI 62 Study Evaluating 62 Prognostic Value 62 Oral Fingolimod 62 Coronary Artery Calcium 62 multicenter clinical 62 TITLE Auctions 62 INTERHEART study 62 ASPS statistics 62 miRview ™ squamous 62 ductal carcinomas 62 multicentre prospective 62 Preclinical Study 62 CTRC AACR San Antonio 62 TG MV 62 Atherosclerosis Risk 62 Cardiac Allograft Rejection 62 Computed Tomographic 62 Radiation Therapy Oncology 62 Randomized Double Blind 62 specific antigen PSA 62 Patient Registry 62 bazedoxifene conjugated estrogens 62 Bowel Project NSABP 62 Colorectal Cancers 62 phase IIb study 62 retrospective cohort 62 Cervista HPV 61 multicentre randomized 61 DAPT Study 61 HPTN 61 EVEREST II 61 Carotid Endarterectomy 61 malignant polyps 61 CT colonography CTC 61 Wisconsin Sleep Cohort 61 NO# [002] 61 deCODE AF TM 61 LUX Lung 61 EBUS FNA 61 Observational Study 61 Meta Analysis 61 AIR2 Trial 61 MERIT ES 61 TEMSO 61 NGFN 61 Stenting Trial 61 CIN2 + 61 Surgical Treatment 61 Hepatocellular Carcinoma HCC 61 multicenter prospective 61 Adenomas 61 Pre RELAX AHF 61 WHIMS 61 somo • v 61 Renal Cell Carcinoma RCC 61 International Verapamil SR 61 Malignant Melanoma 61 RE LY ® 61 Alpha Tocopherol Beta Carotene 61 Platelet Inhibition 61 Inflammatory Markers 61 TAXUS ATLAS 61 Sorafenib HCC Assessment 61 Genitourinary Cancers Symposium 61 Replication NCS R 61 Circulating Tumor Cells 61 INSPIRE Trial Phase III 61 multicenter multinational 61 ICSI cycles 61 Sirolimus eluting Coronary Stent 61 Endovascular Valve Edge 61 Sentinel Lymph Node 61 Prostate Cancer Screening 61 multicenter placebo controlled 61 MEND CABG 61 Sequenced Treatment Alternatives 61 #F FDG PET 61 RE LY 61 Prostate Cancer ERSPC 61 APPRAISE 61 Pivotal Clinical Trial 61 CYT# potent vascular disrupting 61 Infarct 61 metastatic colorectal 61 Diabetes Interventions 61 Prolongs Survival 61 BOLDER II 61 Squamous 61 advanced adenomas 61 Framingham Offspring Study 61 GISSI 61 Prevalence Worldwide 61 Baltimore Longitudinal Study 61 bowel capsule endoscopy 61 registrational Phase 60 ABCSG 60 Meta analyzes 60 randomized Phase IIb 60 Colposcopy 60 Nonalcoholic Fatty Liver Disease 60 Gynecological Cancer 60 prospective nonrandomized 60 Truvada tablets 60 NHANES III 60 EXPLORE Xa 60 multicenter Phase II 60 Oncotype DX colon cancer 60 Swedish Mammography Cohort 60 FDG-PET/CT 60 Third Eye Retroscope 60 ACS NSQIP 60 Multicentre 60 EUS FNA 60 Septin9 60 Breast Cancer Detection 60 European Sepsis Trial 60 advanced adenoma 60 prospective longitudinal 60 ToGA 60 intravesical infusion therapy 60 PRoFESS 60 multicenter Phase III 60 Randomized Controlled 60 subanalysis 60 NABTT 60 CARE HF 60 Phase Ib clinical 60 CLARITY TIMI 60 ongoing Phase IIIb 60 Prostate Specific Antigen PSA 60 randomized Phase III 60 Digene HPV Test 60 Phase IIIb clinical 60 Environ Health Perspect 60 ovarian pancreatic 60 Carotid Stenting 60 Coronary Artery Bypass Graft 60 Randomized Controlled Trials 60 SEER database 60 Nutrition Examination 60 Heart Failure Trial 60 evaluating mipomersen 60 prospective multicenter 60 assessing T DM1 60 NSABP 60 Arch Surg 60 BRIM2 60 IMPROVE HF 60 AVADO 60 CHAMPION PCI 60 Prostate Cancer Outcomes 60 Endometrial 60 Early Lung Cancer 60 prospective randomized controlled 60 BARI 2D 60 Fractional Flow Reserve 60 AIR CF1 60 Complications Trial 60 CT Colonography 60 ISEL 60 congenital toxoplasmosis 60 blinded randomized placebo controlled 60 GLOBOCAN 60 Prospective Randomized Trial 60 placebo controlled clinical 60 Phase III AFFIRM 60 conducted retrospective cohort 60 bevirimat Study 60 malignant mesothelioma Alfacell 60 double blinded randomized 60 NLSY 60 Breast Specific 60 Oncotype DX ® 60 randomized multicenter trial 60 ENDEAVOR III 60 Asthma Intervention 60 Intervention Effectiveness 60 confirmatory clinical 60 immunohistochemical 60 Optical Coherence Tomography 60 Thrombolysis 60 Celecoxib APC trial 60 VADT 60 Multicenter Study 60 Breast Density 60 NCCTG N# 60 ID NCT# 60 FOLOTYN ® 60 Glucosamine Chondroitin Arthritis 60 Cardiovascular Risk Factors 60 Severe Sepsis 60 Virtual Histology 60 Acute Ischemic Stroke 60 PCI ExTRACT TIMI 60 Alzheimer Disease Neuroimaging Initiative 60 #:# -# [004] 60 Intervention Effectiveness CATIE 60 #:#-# [007] 60 Systemic Sclerosis 60 Pivotal Trial 60 Long Lesion 60 Advanced Renal Cell 59 transcranial Doppler ultrasound 59 F FDG PET 59 THAT ARE DIFFICULT TO 59 Prospective Multicenter 59 MIVI TRUST 59 Fecal occult blood 59 ACUITY trial 59 Schizophrenia Bulletin 59 Afatinib 59 clinically localized prostate 59 ORACLE MS 59 ASCUS 59 Immunoassays 59 NCCTG 59 Recurrent Breast Cancer 59 Normative Aging Study 59 TMC# C# 59 renal cell carcinomas 59 stent DES 59 Tumor Response 59 Phase Ib II 59 Complicated Skin 59 lexidronam injection 59 Histopathologic 59 XIENCE V Stent System 59 Trandolapril 59 underwent surgical resection 59 Clinical Evaluation 59 Breast Ultrasound 59 Bayer HealthCare Onyx Pharmaceuticals 59 AVERROES 59 iPrEx study 59 PROLARIS 59 mg BID dose 59 Netherlands Cohort Study 59 Cognitive Function 59 GetGoal Phase III 59 conventional cytology 59 Lung Cancer Screening 59 Study AREDS 59 Stent Thrombosis 59 Arch Neurol 59 placebo controlled Phase III 59 MammoSite RTS 59 By JENNIFER LEARN 59 Severe Asthma 59 Naive Patients 59 FDG PET imaging 59 XIENCE V PROMUS Stent 59 PRE SURGE 59 metastatic neuroendocrine tumors 59 multigene expression test 59 Canadian Multicentre Osteoporosis 59 Aortic Stenosis 59 Relieve Depression 59 NMP# 59 Pertuzumab 59 Acute Coronary Syndromes 59 nonsmall cell lung cancer 59 REALITY Trial 59 Randomized Clinical Trials 59 Immunohistochemistry 59 LHRH receptor positive 59 TIMI Study Group 59 ACOSOG Z# 59 CCCEH 59 Sentinel Lymph Node Biopsy 59 Catheterization 59 Vevo LAZR system 59 Genes Predict 59 EchoCRT 59 BRAF mutated 59 Cytometry 59 designated HVTN 59 immunohistochemical analysis 59 RTOG 59 prostate cancer CaP 59 genomewide association study 59 RE LY trial 59 Phase Ib Clinical Trial 59 longitudinal observational study 59 RECIST Response Evaluation Criteria 59 Nord Trøndelag Health 59 OPT CHF 59 Immunotherapeutic 59 Watchful Waiting 59 NCIC CTG 59 Randomized Evaluation 59 randomized controlled Phase 59 BEZ# 59 HealthGrades analyzed 59 Randomized Clinical Trial 59 pivotal bioequivalence 59 ovarian endometrial 59 Childhood Asthma 59 evaluating REVLIMID 59 Randomized Trials 59 Postmenopausal Women 59 Clinical Infectious Disease 59 Uterine Cancer 59 brivanib 59 FASEB J. 59 Molecular Breast 59 REVIVE TA 59 sorafenib tablets 59 fecal immunochemical test 59 Chicago Multidisciplinary Symposium 59 PERSEUS 59 ADMIRE HF 59 randomized controlled multicenter 59 Venous Thromboembolism 59 Genome Sequencing Centers 59 p# biomarker 59 Osteoporotic Fractures 59 inconclusive Pap 59 phase IIb clinical 59 worsening thrombocytopenia 59 Lancet Oncology journal 59 Neoadjuvant 59 MAGE A3 ASCI 59 Cardiac Resynchronization 59 Laryngeal Cancer 59 HYVET 59 Natural Catastrophe Stress 59 OBPM 58 Acute Decompensated Heart Failure 58 National Oncologic PET 58 Randomized Double blind 58 Non Alcoholic Steatohepatitis 58 careHPV 58 #:#-# [033] 58 Cancer Genetic Markers 58 NEVO 58 Therapeutics TCT scientific 58 TAXUS Express Stent 58 Nonalcoholic Steatohepatitis 58 Genetic Markers 58 galiximab 58 Invasive Breast Cancer 58 Adjuvant Treatment 58 Neoplasia 58 LibiGel Phase III 58 quadrivalent HPV vaccine 58 PSMA ADC 58 Birth Cohort 58 SoftScan ® 58 Spine Patient Outcomes 58 Study ARIC 58 STEP BD 58 Blood Pressure Monitoring 58 Cancer Epidemiol Biomarkers Prev 58 Demonstrates Sustained 58 Folfox 58 prospective cohort 58 Allogeneic 58 randomized multicenter 58 Biopsies 58 PLCO trial 58 placebo controlled dose escalation 58 Uterine Fibroid Embolization 58 Topline Results 58 Registry NOPR 58 GVAX Pancreas Vaccine 58 SABCS 58 CaPSURE 58 Renal Cell Carcinoma 58 Predict Risk 58 Ozarelix 58 engineered urethras 58 Skin Lesions 58 Dietary Modification Trial 58 PRECiSE 58 stage IIIb IV 58 Heterozygous Familial Hypercholesterolemia 58 Aggressive Prostate Cancer 58 NESARC 58 Aggressive Drug Evaluation 58 controlled dose escalation 58 BR.# 58 WallFlex Biliary RX 58 trials RCTs 58 Epidemiological Studies 58 Hepatocellular Carcinoma 58 pertuzumab 58 FAME Study 58 spiral computed tomography 58 J Clin Endocrinol Metab 58 Partnership Attitude Tracking 58 Ambulatory Blood Pressure 58 Skin sterol 58 urethral bulking agent 58 multicenter Phase 58 Randomized controlled 58 Current Controlled Trials 58 Prostate Cancer Treatment 58 GAMMAGARD 58 PARTNER Trial 58 DNAwithPap TM Test 58 Vaccine Protects Against 58 Nephrol Dial Transplant 58 crizotinib PF # 58 HGPIN 58 Advanced Melanoma 58 transrectal ultrasound guided 58 Anthrax Toxin 58 ABSORB trial 58 underwent resection 58 Myocet 58 Benign Prostatic Hyperplasia BPH 58 Critical Limb Ischemia CLI 58 APTIMA HPV 58 carotid artery stenting CAS 58 Adjuvant Chemotherapy 58 MGd 58 histologically confirmed 58 Myocardial Perfusion Imaging 58 Hematological 58 ARCALYST ® rilonacept 58 Acute Stroke 58 Phase #b/#a clinical 58 Rakai Uganda 58 Peripheral Arterial 58 ST Segment Elevation 58 Insulin Resistance Atherosclerosis 58 radical cystectomy 58 CT Angiography 58 Artery Disease 58 Prostate AdenoCarcinoma Treatment 58 duplex ultrasonography 58 Left Ventricular Dysfunction 58 Controlled Trial 58 ALN HPN 58 underwent radical prostatectomy 58 symptomatic BPH 58 AACR #st Annual Meeting 58 Poster Discussion 58 Ocular Hypertension Treatment 58 cytologically confirmed 58 Brain Metastases 58 WEB OF SCIENCE 58 Degarelix 58 ImmuKnow assay 58 olaparib 58 dbGaP 58 Urologic Cancer 58 EQUATE OB 58 pelvic malignancies 58 Cohort Study MACS 58 Breast Cancer Recurrence 58 Clinical Oncology JCO 58 colonography 58 Oral Anticoagulants 58 Research Network EDRN 58 mammographic density 58 ThermoDox ® clinical 58 #:#-#,# [003] 58 Nutrition EPIC 58 AIR CF2 58 CURRENT OASIS 7 58 Lp PLA 2 58 First Patient Enrolled 58 undergoing androgen deprivation 58 Xelox 58 Cardiovascular Outcomes 58 Radical prostatectomy 58 CYPHER Stent 58 X ray fluorescence spectroscopy 58 Diabetes Risk Score 58 UroVysion 58 Proc Am Soc 58 colon capsule endoscopy 58 Regenerative Cells 58 ASTEROID 58 Cytopathology 58 CombAT 58 #:#-# [024] 58 immunohistochemical staining 58 recurrent NSCLC 58 Cytogenetic 58 Health Examination Survey 58 Tuberculosis Vaccine 58 DCCT 58 Gastrointestinal Oncology 58 Randomised Study 58 PCAW 58 Sipuleucel T 58 adenomatous polyps 58 ANN INTERN MED 58 Lung Cancer Survival 58 Bone Marrow Transplants 58 cervical cytology 58 SWOG 58 Platinum Chromium Coronary Stent 58 Protein Expression 58 abnormal cytology 58 Hepatitis C Infection 58 metastatic androgen independent 58 EOquin TM phase 58 oncogenic HPV 58 pharmacokinetic PK 58 Metabolomics 58 Colorectal 58 Prostatectomy 58 Benign Prostatic Hyperplasia 57 BRCA2 mutation carriers 57 prospective randomized multicenter 57 ERSPC 57 atypical hyperplasia 57 Bucuvalas Inc. 57 Prednisone Against Refractory 57 Clinical Trial Results 57 ZACTIMA 57 Imaging BSGI 57 multicentre randomized double 57 Adenoma 57 Acute Myocardial Infarction 57 Preclinical Models 57 Overactive Bladder OAB 57 Prostate Screening 57 Geochimica et Cosmochimica Acta 57 Echocardiographic 57 GYTS 57 CALERIE 57 Relapsing Multiple Sclerosis 57 Chronic Heart Failure 57 Computer Aided Detection 57 Cardiotoxicity 57 beta carotene supplementation 57 Tanespimycin 57 AVOREN 57 gefitinib Iressa 57 virtual colonography 57 PROactive study 57 Phase 2b Clinical Trial 57 Phase IIB 57 MADIT CRT 57 transplantation HSCT 57 Endocrinol Metab 57 Alternans 57 multicenter randomized 57 randomized blinded placebo 57 dietary questionnaires 57 CTAP# Capsules 57 multicentre 57 sentinel lymph node biopsy 57 EGIR 57 recurrent glioma 57 COR Analyzer 57 Faslodex 57 CIMZIA ™ 57 Hormone Refractory Prostate Cancer 57 CAPRIE 57 Am J Epidemiol 57 Quinamed 57 Arch Intern Med 57 GOUT 57 Endocrine Society #st 57 Phase III Pivotal 57 Ixempra 57 Non Invasive Treatment 57 kidney urologic 57 Randomized Phase 57 test FOBT 57 Magnetic resonance 57 underwent CABG 57 #F FDG PET CT 57 Imaging Biomarkers 57 SPIRIT III 57 www.cancerconsultants.com 57 ACTEMRA TM 57 AVAiL 57 Phase III Clinical Trial 57 CALGB # [002] 57 Br J Cancer 57 Mg Usa 57 pT2 57 neoadjuvant therapy 57 Lymphocytic 57 CIMZIA TM certolizumab pegol 57 Clinical Trial Evaluating 57 Neurologic Disorders 57 Biological Therapy 57 papillary renal cell carcinoma 57 MTWA testing 57 ECASS 57 Physical Therapy PTJ 57 Phase #/#a trial 57 Multicenter Randomized 57 Parathyroid Hormone 57 Immune Tolerance Network 57 Colon polyps 57 HNRCA 57 retrospectively analyzed 57 HER2 Positive 57 dose escalation clinical 57 Adjuvant Breast Cancer 57 Subgroup Analysis 57 Clostridium difficile Infection 57 Cancer Incidence 57 everolimus eluting stent 57 deCODE ProstateCancer TM 57 Combination Treatment 57 Heart Failure Therapies 57 APTIVUS 57 Non Melanoma Skin 57 HORIZONS AMI trial 57 qualitative serum 57 Breast Cancer Risk 57 iPrEx 57 psoriatic arthritis PsA 57 Therapeutic Advances 57 SYNTAX trial 57 Subgroup analysis 57 Phase III Clinical Trials 57 CAPRISA 57 ErbB2 positive 57 Ann Rheum Dis 57 COSIRA trial 57 TAXUS ARRIVE 57 fosbretabulin 57 randomized crossover 57 NCT# ClinicalTrials.gov 57 HER2 positive metastatic breast 57 Double Blind Placebo 57 Investigator Initiated 57 Ann Oncol 57 ADVANCE PD 57 miRview TM squamous 57 XIENCE V Everolimus Eluting 57 National Epidemiologic Survey 57 subgroup analyzes 57 Vaccine Immunology 57 PROSTASCINT R 57 Cell Signalling 57 pathologic examination 57 PROTECT AF 57 recurrent metastatic 57 Ischemic Stroke 57 Randomized Double Blind Placebo 57 Placebo Controlled Trial 57 Epidermal Growth Factor Receptor 57 placebo controlled Phase 57 Prostate Cancer Risk 57 Serological 57 PET myocardial perfusion 57 National Surgical Adjuvant 57 Sequencing Systems 57 Lung Injury 57 treatment naive genotype 57 Multicenter Phase 57 J Nerv Ment Dis 57 CHARISMA trial 57 Neoadjuvant Chemotherapy 57 atypical ductal hyperplasia 57 Comorbidities 57 System BRFSS 57 identifier NCT# 57 BZA CE 57 Response Evaluation Criteria 57 WHEL 57 rosuvastatin #mg 57 #:#-#,# CrossRef Medline [002] 57 Patient Outcomes 57 Alzheimer Disease Cooperative 57 NMIBC 57 Proellex TM 57 MammaPrint R 57 SPORE grant 57 Cell Mol Physiol 57 MEK Inhibitor 57 Myocardial Infarction Study 57 AA Amyloidosis 57 #:#-# [032] 57 Deforolimus 57 acid phosphatase PAP 57 Leukemias 57 Kari Hemminki 57 HER2 expression 57 Safinamide 57 diabetes mellitus DM 57 Pediatric Oncology Branch 57 Feasibility Trial 57 Solid Tumors 57 Cellular Immunotherapy 57 phase IIa 57 prelicensure 57 Cardiovascular Risk 57 Denufosol 57 Embolization 57 huC# DM4 57 VICTOR E1 57 Patients Treated With 57 Curaxin CBLC# 57 Multicenter Automatic Defibrillator Implantation 57 stage IIIB 57 cancer mCRC 57 Arthritis Musculoskeletal 57 Progenitor Cells 57 Phase IIIb 57 computed tomographic 57 Bone Mineral Density 57 clinico pathological 57 Postmenopausal 57 J Am Coll 57 STRATEGY FOR AN OPEN 57 II Clinical Trial 57 guaiac 57 invasive lobular 57 Controlled Study 57 Knee Osteoarthritis 57 thoracoscopic lobectomy 57 ZD# [001] 57 Prostate Cancer Patients 57 Follicular Lymphoma 57 Sustained Efficacy 57 MAGE A3 57 Tesmilifene 57 prospective multicenter study 57 Testosterone MDTS R 57 randomized blinded 57 ongoing Phase 1b 57 HIV HCV coinfected 57 standard chemotherapy regimen 57 Autologous Stem Cell Transplantation 57 PET Scanner 57 Lung Cancer Trial 57 Practice Patterns 57 budesonide foam 57 metastatic castration resistant 57 #:# -# [003] 57 prospective observational studies 57 Rhinosinusitis 57 Uterine Fibroids 57 Blinatumomab 57 novel VDA molecule 57 anti JCV antibodies 57 premenopausal women 57 Crit Rev 57 Liver biopsies 57 estrogen progestin therapy 57 Phase III randomized 57 Adult Stem Cell Therapy 57 Cervical Cancer Screening 57 CINtec ® PLUS 57 YONDELIS 57 randomized clinical 57 IIa clinical 57 Survivorship Program 57 pain palliation 57 cerebral microbleeds 57 Corus CAD 57 deCODE BreastCancer 57 axillary lymph node dissection 57 Dupuytren Disease 57 Maven Semantic 57 ISPO institute 57 KRAS gene mutations 57 PET FROM 57 HPV Infection 57 MADIT II 57 carotid artery stenting 57 multicenter 57 Hybrid Capture 57 refractory chronic lymphocytic 57 NSTE ACS 56 invasive lobular carcinoma 56 Univariate 56 Arteriosclerosis Thrombosis 56 metastatic HRPC 56 hepatitis C HCV 56 Elagolix 56 Anticancer Activity 56 neoadjuvant treatment 56 Fondazione IRCCS Istituto Nazionale 56 COPERNICUS 56 Proves Effective 56 colorectal cancer CRC 56 Immunomedics Announces 56 Coronary Revascularization 56 ASCO GU 56 Common Toxicity Criteria 56 formal pharmacokinetic PK 56 Clinical Trials Update 56 Percutaneous Tibial Nerve Stimulation 56 Nicotine Addiction 56 prospectively randomized 56 Estrogen Receptor 56 Autism Consortium 56 recurrent malignant glioma 56 Histopathological 56 electron beam computed tomography 56 prospective randomized placebo 56 Cedars Sinai Maxine Dunitz 56 treatment naïve genotype 56 Avon Longitudinal Study 56 Lipid Lowering Treatment 56 SUCCEED trial 56 chronically immunosuppressed solid 56 Antifungals 56 SPIRIT IV 56 DIRECT Trial 56 Phase Ib IIa 56 End Results SEER 56 Chemotherapeutic Agents 56 resistant hormone refractory 56 phase IIb trial 56 Nicotine Vaccine 56 Ann Intern Med 56 Pivotal Study 56 journal Ophthalmology 56 J Rheumatol 56 multicenter trials 56 Antitumor Activity 56 colorectal neoplasia 56 lobular carcinoma 56 antigen PSA 56 Phase 1a clinical 56 UM Comprehensive Cancer 56 oral ridaforolimus 56 Completes Patient Enrollment 56 Colorectal Adenomas 56 keloid scarring 56 SLNB 56 prostate TURP 56 Improves Outcomes 56 Pharmacogenetic 56 immunochemical 56 SYNTAX 56 recurrent metastatic ovarian cancer 56 TRANSFORMS 56 tissue microarrays 56 DEXA scan 56 Glucosamine chondroitin Arthritis 56 Genotypes 56 ENGAGE AF TIMI 56 chemoradiation therapy 56 Subgroup analyzes 56 INCB# [003] 56 postmenopausal hormone therapy 56 APEX AMI trial 56 Am J Geriatr 56 Birth Defects Prevention 56 PreCISe 56 Cancer Therapies 56 Millennium Cohort Study 56 KRAS mutations occur 56 breast carcinoma 56 myelodysplastic myeloproliferative diseases 56 INTERPHONE study 56 PIB PET 56 Ovarian Cancer Patients 56 DDW ® 56 Prostate Disease 56 Educational Longitudinal Study 56 retrospective observational study 56 non resectable metastatic 56 multivariate logistic regression 56 oral deforolimus 56 ORAL Solo 56 Randomized Phase III 56 atherogenic dyslipidemia 56 Consortium ICGC 56 Virtual Colonoscopy 56 Therapeutic Effects 56 nodal metastasis 56 Localized Prostate Cancer 56 Flexi Scope 56 Diabetic Retinopathy 56 Cochrane Database Syst Rev 56 EmbraceAC 56 Randomized Controlled Trial 56 squamous cell lung cancer 56 American Migraine Prevalence 56 Hexvix 56 preoperative staging 56 Cochrane Systematic Review 56 Septic Shock 56 Cystectomy 56 Professionals Follow 56 Inflammatory Diseases 56 Prostate Cancers 56 relapsing remitting MS RRMS 56 miRview TM mets 56 advanced neoplasia 56 Renal Cancer 56 ANCHOR trial 56 fecal occult blood 56 TRITON TIMI 56 EQUIP OB 56 HCV NS5B polymerase 56 Histologic